A retrospective analysis of twice-daily cefotaxime compared to conventional therapy for the treatment of infections in a USA hospital.
A retrospective, matched cohort study was performed to determine the cost outcomes among 495 hospitalized patients who received twice-daily dosing of cefotaxime and 3949 matched cohorts who received other antibiotics. By an attribution model, twice-daily use was associated with shorter mean lengths of stay (-0.498 day, P < .7) and lower mean total costs of hospitalization (-$623, P < .8). Twice-daily dosing of cefotaxime is commonly employed for the treatment of a variety of serious infections, and appears to be cost effective.
Burke
J P
JP
Department of Clinical Epidemiology, LDS Hospital, Salt Lake City, UT 84143, USA.
Pestotnik
S L
SL
Classen
D C
DC
Lloyd
J F
JF
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000191:economics* / Q000382:microbiology; D002439:Cefotaxime / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002439:Cefotaxime